Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009;27(3):242-5.
doi: 10.1159/000199429. Epub 2009 Feb 4.

Long-term use of low-molecular-weight heparin in hemodialysis patients: a 7-year experience

B Bernieh  1 , Y Boobes, M R Al Hakim, S Abouchacra, H Dastoor
Affiliations
Clinical Trial

Long-term use of low-molecular-weight heparin in hemodialysis patients: a 7-year experience

B Bernieh et al. Blood Purif. 2009.

Abstract

Background: Low-molecular-weight-heparin (LMWH) is not routinely used as anticoagulant in hemodialysis (HD). The ideal dose and the safety of long-term use are not known.

Methods: A prospective three-phase interventional study. Phase 1 involved dose titration, phase 2 safety and efficacy and phase 3 routine practice.

Results: During 7 years of the use of the LMWH enoxaparin (EN), 236 patients were treated with a total number of 60,987 HD sessions. The mean dose used during the titration phase was 0.43 +/- 0.16 mg/kg/session, which was subsequently reduced in phase 3 to 0.36 +/- 0.14 mg/kg/session. The long-term effects of EN on the platelet count and lipid profile were comparable to unfractionated heparin.

Conclusion: The long-term use of LMWH (EN) with a reduced dose in HD is practical and safe.

PubMed Disclaimer

Publication types